Thermo Fisher Scientific INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
Thermo Fisher Scientific reports strong Q2 2026 results with revenue and earnings exceeding expectations, driven by robust performance across its segments and strategic acquisitions.
NYSE
Thermo Fisher Scientific reported Q1 2026 revenue of $11.0 billion, a 6% increase, driven by strong pharma and biotech demand and the acquisition of Clario Holdings.
NYSE
Thermo Fisher Scientific Inc. reported a 5% increase in Q3 revenues and a 10% rise in adjusted EPS, driven by strategic acquisitions and productivity gains, despite some market headwinds.
NYSE
Thermo Fisher Scientific Inc. reported a 2% increase in total revenues for the first six months of 2025, reaching $21.22 billion, alongside a 10% rise in GAAP diluted EPS, but experienced a significant 43% decline in free cash flow.
NYSE
10-Q: Thermo Fisher Scientific Reports Slight Revenue Increase in Q1 2025, Maintains Full-Year Guidance
Thermo Fisher Scientific's Q1 2025 results show a slight revenue increase and reaffirmation of their growth strategy.
NYSE
Thermo Fisher Scientific's third-quarter results show flat revenue growth and a decrease in earnings per share, impacted by reduced COVID-19 related demand and a muted macroeconomic environment.
NYSE
Thermo Fisher Scientific's second quarter results show a slight revenue decrease and mixed performance across segments, impacted by reduced COVID-19 related demand and a muted macroeconomic environment.
NYSE
Thermo Fisher Scientific's first quarter 2024 results show a revenue decrease of 3% year-over-year, primarily due to reduced demand for COVID-19 related products and a challenging macroeconomic environment.